Shares of Unum Therapeutics Inc (NASDAQ:UMRX) hit a new 52-week low on Monday . The company traded as low as $7.22 and last traded at $7.25, with a volume of 27889 shares. The stock had previously closed at $7.64.
UMRX has been the subject of a number of analyst reports. Cowen reaffirmed a “hold” rating on shares of Unum Therapeutics in a research report on Monday, September 17th. Wedbush boosted their price target on Unum Therapeutics from $18.00 to $20.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 14th. Morgan Stanley boosted their price target on Unum Therapeutics from $20.00 to $21.00 and gave the stock an “overweight” rating in a research report on Thursday, October 11th. Finally, Zacks Investment Research cut Unum Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, October 17th. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $20.67.
Unum Therapeutics (NASDAQ:UMRX) last posted its quarterly earnings data on Monday, August 13th. The company reported ($0.31) earnings per share for the quarter, topping the consensus estimate of ($0.33) by $0.02. The business had revenue of $1.67 million for the quarter, compared to analyst estimates of $2.45 million. As a group, equities analysts forecast that Unum Therapeutics Inc will post -1.56 EPS for the current fiscal year.
In related news, insider Seth Ettenberg sold 11,485 shares of the business’s stock in a transaction dated Thursday, October 25th. The stock was sold at an average price of $8.46, for a total transaction of $97,163.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
A number of institutional investors have recently bought and sold shares of the business. Bank of New York Mellon Corp acquired a new position in Unum Therapeutics in the 2nd quarter valued at approximately $177,000. Spark Investment Management LLC acquired a new position in Unum Therapeutics in the 2nd quarter valued at approximately $186,000. Wasatch Advisors Inc. raised its holdings in Unum Therapeutics by 5.3% in the 2nd quarter. Wasatch Advisors Inc. now owns 267,625 shares of the company’s stock valued at $3,840,000 after acquiring an additional 13,525 shares in the last quarter. Keybank National Association OH bought a new stake in shares of Unum Therapeutics in the 2nd quarter valued at approximately $195,000. Finally, JPMorgan Chase & Co. grew its stake in shares of Unum Therapeutics by 2,782.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 20,753 shares of the company’s stock valued at $213,000 after purchasing an additional 20,033 shares during the period. 51.50% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION WARNING: This article was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this article on another website, it was stolen and republished in violation of United States & international copyright law. The legal version of this article can be read at https://www.dispatchtribunal.com/2018/11/07/unum-therapeutics-umrx-reaches-new-12-month-low-at-7-22.html.
About Unum Therapeutics (NASDAQ:UMRX)
Unum Therapeutics Inc, a clinical stage biopharmaceutical company, develops and commercializes immunotherapy products designed to harness the power of a patient's immune system to cure cancer. Its lead product candidate is the ACTR087 used in combination with rituximab, which is in Phase I clinical trials to treat adult patients with relapsed or refractory non-Hodgkin lymphoma.
Featured Story: How is Preferred Stock Different from Common Stock?
Receive News & Ratings for Unum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.